ArticleJournal of Ayurveda and integrative medicine
A preliminary study on Tapyadi Loha for the treatment of hepatic encephalopathy based on Insilico and Invitro analysis.
Article in Journal of Ayurveda and integrative medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatic encephalopathy (HE) is a neuropsychiatric disorder linked to liver dysfunction, commonly occurring in cirrhosis or acute liver failure. Existing treatments like lactulose and rifaximin provide only symptomatic relief and cause gastrointestinal side effects, emphasizing the need for alternative therapies. Tapyadi Loha (TL), a classical Ayurvedic herbomineral formulation, is traditionally used in clinical practice for HE lacks scientific evidence.
objectivesTo perform preliminary evaluation of TL in the management of HE through in silico and in vitro analysis. MATERIAL AND
methodsActivity markers of TL were screened using IMPPAT, SwissADME, and MolSoft based on ≥30 % oral bioavailability and drug-likeness scores of 0-1. Potential HE-related targets were identified through SwissTarget Prediction, SuperPred, BindingDB, and GeneCards, with overlapping targets analyzed via PPI networks using STRING and Cytoscape. Molecular docking in Schrodinger's Maestro revealed good binding affinity phytoconstituents, which were quantified by LC-MS/MS as per CCRAS guidelines. Their hepatoprotective activity was validated in HepG2 cells, while antioxidant effects were confirmed using the DPPH assay.
resultsGene ontology and KEGG analyses revealed enrichment in cancer and hepatitis B pathways, notably NF-κB, TNF, and TLR signalling. Docking studies identified strong binding of gallic acid, quercetin, ascorbic acid, and luteolin, validated by LC-MS/MS. In vitro, TL treatment significantly improved HepG2 cell viability in thioacetamide-induced toxicity in a dose dependent manner, confirming its hepatoprotective potential. Additionally, TL demonstrated antioxidant activity in the DPPH assay.
conclusionThe study examined the potential molecular targets, important genes, and signalling pathways of TL and its connection to HE using a network pharmacology approach. HepG2 cell line research showed that TL increased cell viability in a dose-dependent way. The study supports TL's possible neuroprotective and hepatoprotective benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.